Super-response to sacubitril valsartan: prevalence and clinical profile

被引：0
|
作者：
Moliner Abos, C. [1 ]
Rivas-Lasarte, M. [2 ]
Pamies Besora, J. [1 ]
Fluvia Brugues, P. [1 ]
Sole-Gonzalez, E. [1 ]
Mirabet, S. [1 ]
Lopez Lopez, L. [1 ]
Brossa, V. [1 ]
Mesado, N. [1 ]
Pirla, M. J. [1 ]
Roig, E. [2 ]
Alvarez-Garcia, J. [2 ]
机构：
[1] Hosp Santa Creu & Sant Pau, Barcelona, Spain
[2] Hosp Santa Creu & Sant Pau, CIBERCV, Cardiol, IIb St Pau, Barcelona, Spain
来源：
EUROPEAN JOURNAL OF HEART FAILURE | 2019年 / 21卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P1174
引用
收藏
页码：290 / 291
页数：2
相关论文
共 50 条
  • [41] Potential predictors of non-response and super-response to cardiac resynchronization therapy
    Qiao Qing
    Ding Li-gang
    Hua Wei
    Chen Ke-ping
    Wang Fang-zheng
    Zhang Shu
    CHINESE MEDICAL JOURNAL, 2011, 124 (09) : 1338 - 1341
  • [42] Foreseeing Super-Response to Cardiac Resynchronization Therapy A Perspective for Clinicians
    Ellenbogen, Kenneth A.
    Huizar, Jose F.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2012, 59 (25) : 2374 - 2377
  • [43] Potential predictors of non-response and super-response to cardiac resynchronization therapy
    QIAO QingDING LigangHUA WeiCHEN KepingWANG Fangzheng and ZHANG Shu Centre of Arrhythmia Diagnosis and TreatmentFuwai Hospital Chinese Academy of Medical SciencesPeking Union Medical CollegeBeijing China
    中华医学杂志（英文版）, 2011, (09) : 1338 - 1341
  • [44] Potential predictors of non-response and super-response to cardiac resynchronization therapy
    Qiao, Qing
    Ding, Li-gang
    Hua, Wei
    Chen, Ke-ping
    Wang, Fang-zheng
    Zhang, Shu
    CARDIOLOGY, 2011, 120 : 81 - 82
  • [45] LV only fusion pacing CRT without RV lead: clinical and echocardiographic characteristics of super-response
    Vacarescu, C.
    Petrescu, L.
    Luca, C. T.
    Mornos, C.
    Goanta, E. V.
    Crisan, S.
    Cozma, D.
    EUROPEAN JOURNAL OF HEART FAILURE, 2019, 21 : 373 - 373
  • [46] Should All Heart Failure Patients Be Treated With Sacubitril/Valsartan? Response
    Packer, Milton
    JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS, 2018, 23 (01) : 99 - 100
  • [47] The clinical profile of a non-selected population treated with sacubitril/valsartan is different from PARADIGM-HF trial
    Vicent Alaminos, L. Lourdes
    Esteban Fernandez, A.
    Gomez Bueno, M.
    De Juan, J.
    Diez Villanueva, P.
    Iniesta, A. M.
    Ayesta, A.
    Gonzalez Saldivar, H.
    Rojas, A.
    Bover Freire, R.
    Iglesias, D.
    Garcia Aguado, M.
    Perea Egido, J. A.
    Martinez-Selles, M.
    EUROPEAN JOURNAL OF HEART FAILURE, 2018, 20 : 9 - 9
  • [48] Implementation of sacubitril/valsartan in Sweden: clinical characteristics, titration patterns, and determinants
    Fu, Michael
    Vedin, Ola
    Svennblad, Bodil
    Lampa, Erik
    Johansson, Daniel
    Dahlstrom, Ulf
    Lindmark, Krister
    Vasko, Peter
    Lundberg, Anna
    Costa-Scharplatz, Madlaina
    Lund, Lars H.
    ESC HEART FAILURE, 2020, 7 (06): : 3633 - 3643
  • [49] Titration and Tolerability of Sacubitril/Valsartan for Patients With Heart Failure in Clinical Practice
    Du, Amy X.
    Westerhout, Cynthia M.
    McAlister, Finlay A.
    Shanks, Miriam
    Oudit, Gavin Y.
    Paterson, David Ian
    Hanninen, Mikael
    Thomas, Jissy
    Ezekowitz, Justin A.
    JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 2019, 73 (03) : 149 - 154
  • [50] Sacubitril/Valsartan in Daily Clinical Practice: Data From a Prospective Registry
    Vicent, Lourdes
    Esteban-Fernandez, Alberto
    Gomez-Bueno, Manuel
    De-Juan, Javier
    Diez-Villanueva, Pablo
    Manuel Iniesta, Angel
    Ayesta, Ana
    Gonzalez-Saldivar, Hugo
    Rojas-Gonzalez, Antonio
    Bover-Freire, Ramon
    Iglesias, Diego
    Garcia-Aguado, Marcos
    Perea-Egido, Jesus A.
    Martinez-Selles, Manuel
    JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 2019, 73 (02) : 118 - 124
12345